Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 5,147 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRYGet Free Report) CEO Richard E. Lowenthal sold 5,147 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $9.05, for a total transaction of $46,580.35. Following the transaction, the chief executive officer now directly owns 1,642,193 shares of the company’s stock, valued at $14,861,846.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

ARS Pharmaceuticals Stock Down 0.8 %

Shares of ARS Pharmaceuticals stock opened at $9.03 on Friday. The company has a 50-day simple moving average of $9.07 and a two-hundred day simple moving average of $7.02. ARS Pharmaceuticals, Inc. has a 52-week low of $2.55 and a 52-week high of $11.27.

ARS Pharmaceuticals (NASDAQ:SPRYGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). As a group, analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its position in shares of ARS Pharmaceuticals by 22,300.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after buying an additional 5,575 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in ARS Pharmaceuticals in the 1st quarter worth about $60,000. AJOVista LLC bought a new position in ARS Pharmaceuticals during the 4th quarter valued at about $43,000. Paloma Partners Management Co purchased a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at about $103,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of ARS Pharmaceuticals by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after acquiring an additional 8,652 shares during the last quarter. Hedge funds and other institutional investors own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SPRY. SVB Leerink raised shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $6.00 to $18.00 in a research note on Tuesday, March 5th. Leerink Partnrs upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th. William Blair upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th. Finally, Wedbush reissued an “outperform” rating and issued a $19.00 target price on shares of ARS Pharmaceuticals in a research note on Monday, March 11th.

Get Our Latest Analysis on ARS Pharmaceuticals

About ARS Pharmaceuticals

(Get Free Report)

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Featured Stories

Insider Buying and Selling by Quarter for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.